It is made available under a CC-BY-NC-ND 4.0 International license . Neurodevelopmental and Psychiatric Signatures of Genomic Disorders

1 Title Page

2

- 3 Article Title
- 4 Identifying the neurodevelopmental and psychiatric signatures of genomic disorders
- 5 associated with intellectual disability

6

7 Authors

- 8 Nicholas A Donnelly^{1,2}, Adam C Cunningham³, Matthew Bracher-Smith³, Samuel Chawner³,
- 9 Jan Stochl^{5,6}, Tamsin Ford⁶, F Lucy Raymond⁶, Valentina Escott-Price³, Marianne BM van

10 den Bree³

- 11 ¹Centre for Academic Mental Health, Population Health Sciences, University of Bristol, UK
- 12 ² MRC Integrative Epidemiology Unit, Population Health Sciences, Bristol Medical School,
- 13 University of Bristol, UK.
- ³MRC Centre for Neuropsychiatric Genetics and Genomics, Division of Psychological
- 15 Medicine and Clinical Neurosciences, Cardiff University School of Medicine, Cardiff, UK.
- 16 ⁴ Department of Psychiatry, University of Cambridge, Cambridge, UK
- 17 ⁵ Department of Kinanthropology, Charles University, Prague, Czechia
- 18 ⁶ Department of Psychiatry, University of Cambridge, Cambridge, UK

19

- 20 Address correspondence to: Professor Marianne van den Bree, Institute of Psychological
- 21 Medicine and Clinical Neurosciences, Cardiff University School of Medicine, Hadyn Ellis
- 22 Building, Maindy Road, Cathays, Cardiff, CF24 4HQ, [vandenBreeMB@cardiff.ac.uk]

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Neurodevelopmental and Psychiatric Signatures of Genomic Disorders

Author Contributions 23

- 24 Nicholas Donnelly: Methodology, Software, Formal analysis, Data Curation, Visualisation,
- 25 Writing – Original Draft, Writing – Review & Editing
- 26 Adam Cunningham: Methodology, Software, Formal analysis, Data Curation
- 27 Matthew Bracher-Smith: Methodology
- 28 Samuel Chawner: Conceptualisation, Investigation, Writing - Review & Editing, Funding
- 29 acquisition
- 30 Jan Stochl: Methodology, Writing - Review & Editing
- 31 Tamsin Ford: Writing – Review & Editing, Funding acquisition
- 32 F Lucy Raymond: Conceptualisation, Writing – Review & Editing, Funding acquisition
- 33 Valentina Escott-Price: Conceptualisation, Methodology, Writing - Review & Editing,
- 34 Funding acquisition
- 35 Marianne BM van den Bree: Conceptualisation, Writing – Review & Editing, Funding
- 36 acquisition, Project administration, Supervision
- 37
- **Conflicts of Interest Statement** 38
- The authors declare no conflicts of interest 39
- 40

Ethical standards 41

- The authors assert that all procedures contributing to this work comply with the ethical 42
- 43 standards of the relevant national and institutional committees on human experimentation
- and with the Helsinki Declaration of 1975, as revised in 2008. 44
- 45

Neurodevelopmental and Psychiatric Signatures of Genomic Disorders

Funding Statement 46

- 47 This research was funded by the Baily Thomas Charitable Fund (TRUST/VC/AC/SG/5196-
- 48 8188; MvdB), and NIMH (U01 MH119738-01; MvdB), an NIHR clinical lectureship award
- 49 (NAD), and SJRAC is funded by a Medical Research Foundation Fellowship (MRF-058-0015-
- 50 F-CHAW). The IMAGINE-ID study (MvdB) was funded by Medical Research Council grants
- 51 MR/L011166/1, MR/T033045/1 and MR/N022572/1.

Neurodevelopmental and Psychiatric Signatures of Genomic Disorders

52 Abstract

53 Introduction

54 Genomic conditions can be associated with developmental delay, intellectual disability and

55 physical and mental health symptoms, but are individually rare and variable, which limits the

56 use of standard clinical guidelines. A simple screening tool to identify young people with

57 genetic conditions associated with neurodevelopmental disorders (ND-GC) who could

58 benefit from further support would be of considerable value. We used machine learn

59 approaches to address this question.

60 Methods

A total of 489 individuals were included: 376 with a ND-GC, mean age=9.33, 63% male) and

62 113 unaffected siblings; mean age=10.35, 50% male). Primary carers completed detailed

63 assessments of behavioural, neurodevelopmental and psychiatric symptoms and physical

64 health conditions. Machine learning techniques (elastic net regression, random forests,

65 support vector machines and artificial neural networks) were used to develop classifiers of

66 ND-GC status using a limited set of variables. Exploratory Graph Analysis was used to

67 understand associations within the final variable set.

68 Results

69 We identified a set of 30 variables best discriminating between ND-GC carriers and control

individuals, which formed 4 dimensions: Anxiety, Motor Development, Insomnia and

71 Depression. All methods showed high discrimination accuracy with Linear Support Vector

machines outperforming other methods (AUROC between 0.959 and 0.971).

73 Conclusions

In this study we developed models that identified a compact set of psychiatric and physical
health measures that differentiate individuals with a ND-GC from controls and highlight the
structure within these measures. This work is a step toward developing of a screening

Neurodevelopmental and Psychiatric Signatures of Genomic Disorders

- instrument to select young people with ND-GCs who might benefit from further specialist 77
- 78 assessment.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Neurodevelopmental and Psychiatric Signatures of Genomic Disorders

79 Introduction

80 Up to 20% of patients with a neurodevelopmental disorder have an identifiable genomic 81 condition (1–4). Such conditions include copy number variants, single nucleotide variants 82 and aneuploidies, which we collectively call neurodevelopmental genomic conditions (ND-83 GC). ND-GCs have been associated with schizophrenia (5), attention deficit hyperactivity 84 disorder (ADHD), autism spectrum disorder (ASD) (6), and intellectual disability (ID) (7). 85 The clinical presentation of ND-GCs is variable and complex. For example, children with 22g11.2 deletion syndrome, a disorder caused by a deletion in the g11 region of 86 87 chromosome 22, have a high risk of developmental delay and intellectual disability (8), 88 seizures (57%) (9), motor coordination problems (81%) (10), sleep disturbances (60%) (11) 89 and psychiatric disorders (12). Such complex presentation is not unique to 22q11.2 deletion 90 but is typical for many ND-GCs (13), as is incomplete and variable penetrance (14,15). 91 It is therefore extremely important for families of a child with an ND-GC to be informed about 92 the impact that the variant may have on their child's development, so that they can obtain 93 the best possible support. Additionally, clinicians, such as psychiatrists in CAMHS and 94 community learning disability services, who care for affected children after diagnosis are 95 challenged by complex presentations where symptoms which may require input from 96 multiple clinical specialities are present.

97 This problem can be exacerbated by variability in the conditions that present in children with 98 a ND-GCs, which may not follow the expected symptom patterns based on research from 99 non-genotyped populations. For example, we have observed that children with 22g11.2 100 deletion and ADHD are much more likely to be affected with an inattentive subtype than the 101 children with idiopathic ADHD (16). A clinician who is unaware of this may be less likely to 102 diagnose ADHD, meaning that the child misses beneficial treatment. Diagnostic 103 overshadowing may also take place, a well-recognised phenomenon where difficulties that 104 are experienced by a child with a genomic disorder are interpreted as wholly due to ID (17-

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Neurodevelopmental and Psychiatric Signatures of Genomic Disorders

- 105 19). This can reduce the chance for referral to appropriate services and access to
- 106 appropriate treatment (20,21).
- 107 One solution to these problems would be to identify patterns of neurodevelopmental and
- 108 physical health symptoms that are most associated with carrying a ND-GCs, to stratify
- 109 affected patients for graded approaches to investigation and treatment. In the present study,
- 110 we identify those symptoms that most robustly differentiate between children with ND-GCs
- and typically developing control siblings, and analyse whether these symptoms form broader
- symptom domains, using a large sample of children with a wide range of ND-GCs and deep
- 113 physical and mental health phenotyping.

Neurodevelopmental and Psychiatric Signatures of Genomic Disorders

Methods and Materials 114

- **Participants** 115
- 116 We defined ND-GCs as conditions associated with increased risk of neurodevelopmental
- 117 symptoms (22) and caused by a genetic variant which was either pathogenic or likely
- 118 pathogenic, according to American College of Medical Genetics and Genomics guidance
- 119 (23). We aimed to recruit a population of participants with a range of ND-GCs that
- 120 represented a "snapshot" of presentations to UK CAMHS, intellectual disability, clinical
- 121 genetics or community paediatrics clinics.
- 122 Families of children with ND-GCs were recruited through UK Medical Genetics clinics, word
- 123 of mouth and the charities UNIQUE (https://rarechromo.org) and MaxAppeal!
- (https://www.maxappeal.org.uk), as part of ongoing cohort studies at Cardiff University 124
- including the ECHO study (https://www.cardiff.ac.uk/cy/centre-neuropsychiatric-genetics-125
- 126 genomics/research/themes/developmental-psychiatry/copy-number-variant-research-group)
- and the IMAGINE study (https://imagine-id.org) (13,22). 127
- 128 In total 589 individuals (441 individuals with a ND-GC and 148 unaffected control siblings)
- 129 were included in the study, from whom data from 489 individuals was included in our
- 130 machine learning analysis after initial data preparation (Supplementary Methods). Our
- 131 sample size was the maximum number of participants in our dataset who had all the
- required variables. 132

133 Informed, written consent was obtained prior to recruitment from the carers of participants 134 and recruitment was carried out in agreement with protocols approved by relevant NHS and 135 university research ethics committees. Individual ND-GC genotypes were established from 136 medical records and in-house genotyping at the Cardiff University MRC Centre for 137 Neuropsychiatric Genetics and Genomics using microarray analysis. Participant genotypes 138 are shown in Supplementary Table 1.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Neurodevelopmental and Psychiatric Signatures of Genomic Disorders

139 Assessments

- 140 Primary carers of participants completed a battery of assessments to collect comprehensive
- 141 information on physical and mental health problems through semi-structured interview with
- 142 trained research staff and questionnaires. Assessments were carried out between January
- 143 2011 and December 2019. Our goal was to generate a set of items that could be easily and
- 144 conveniently completed by a carer or community clinician either on paper or online.
- 145 Therefore, measures which involved complex or invasive testing, such as cognition or blood
- 146 tests, were not included in our analysis.
- 147 Psychiatric symptoms were measured using the Child and Adolescent Psychiatric
- 148 Assessment (CAPA, (24)), Strengths and Difficulties Questionnaire (SDQ, (25)) and the
- 149 Social Communication Questionnaire (SCQ, (26)). The CAPA assesses domains including
- 150 ADHD, anxiety disorders, oppositional defiant disorder, obsessive compulsive disorder,
- 151 psychosis and psychotic experiences, tic disorders, mood disorders, and substance abuse.
- 152 The SDQ is a dimensional measure of psychopathology that includes measures of
- 153 hyperactivity, emotional problems, peer problems, and prosocial behaviour. The SCQ
- 154 measures ASD-associated symptoms and was used as the CAPA and SDQ lack of
- 155 coverage of ASD symptoms.
- 156 Additionally, as mounting evidence indicates difficulties with coordinated movement are an
- 157 important symptom in individuals with ND-GCs (10,13,27,28), we assessed coordination
- using the developmental coordination questionnaire (DCDQ, (29)).
- 159 Information about physical health problems and development was collected through a
- 160 questionnaire including questions asking about presence or absence of heart problems,
- 161 seizures, musculoskeletal problems, and respiratory problems.
- 162 Statistical Analysis and Data Availability
- 163 All statistical analysis was carried out in R version 4.2.1 (30). An overview of the analysis
- 164 workflow is presented in **Figure 1**. Code used in the project is provided in a GitHub

It is made available under a CC-BY-NC-ND 4.0 International license . Neurodevelopmental and Psychiatric Signatures of Genomic Disorders

- 165 repository <u>https://github.com/NADonnelly/nd_cnv_ml</u> and fitted models are presented as an
- 166 interactive Shiny app: <u>https://nadonnelly.shinyapps.io/cnv_ml_app/</u>. Data from the IMAGINE
- 167 study is available via the IMAGINE ID study website: <u>https://imagine-id.org/healthcare-</u>
- 168 professionals/datasharing/. Analysis is reported in line with the TRIPOD guidelines,
- 169 Supplementary Table 2 (31). An early version of this manuscript was deposited as a
- 170 preprint: .
- 171 Dimensional Structure Assessment
- 172 We applied principal components analysis (PCA) followed by partial least squares
- 173 discriminant analysis (PLSDA, where the outcome was ND-GC status) to explore the
- dimensional structure of our dataset, using the *mixOmics* package (32). A cross-validation
- 175 process was used find the optimal number of components and variables for the PLSDA
- 176 (Supplementary Methods).
- 177 Machine Learning (ML) Model Fitting
- 178 We prepared our data for ML model fitting by splitting participants into a training dataset of
- 390 (80% of the dataset) and a test set of 99 (20% of the dataset), stratifying by ND-GCstatus.
- 181 Our outcome was binary classification of ND-GC status (carrier vs control), and we
- 182 evaluated model performance using the area under the receiver operator characteristic
- 183 curve (AUROC). We used elastic net regression (using the *glmnet* package (33)), random
- 184 forests (using the *Ranger* package (34)), linear support vector machines (SVMs, using the
- 185 *kernlab* package (35)) and single layer artificial neural networks (using the *nnet* package
- 186 (36)) to create models capturing linear and non-linear relationships.
- 187 Models were fit using nested cross-validation (CV), with 20 outer folds and 20 inner folds.
- 188 Outer folds were generated by splitting the data into 5 folds, repeated 4 times. Inner folds
- 189 were generated from the outer fold analysis set using bootstrapping with replacement.

Neurodevelopmental and Psychiatric Signatures of Genomic Disorders

- 190 Within each outer fold missing data was imputed using bagged tree models (37) and the
- 191 same model was used to impute missing data in the analysis set.
- 192 Grid search (30 elements) was used to optimise hyperparameters for ML models across
- 193 inner folds. Model performance was evaluated by fitting the model with the best performing
- 194 set of hyperparameters in the inner fold data to the (previously unseen) outer fold
- assessment dataset. This process was then repeated for all outer folds.
- 196 Following nested CV, we selected models with the highest AUROC, and evaluated the
- 197 importance of all included variables for model prediction using permutation testing (38). We
- selected the top 30 variables for all ML models and generated two further variable sets: all
- 199 variables which were included in the top 30 most important for more than one ML model,
- and those variables included in the top 30 for at least 3 models, to give a total of 6 sets of
- 201 variables.
- 202 We extracted 30 variables for each model because we wanted to achieve a balance
- 203 between accurate prediction, including a wide set of variables for exploration of dimensional
- structure and limiting the number of items to that which could be realistically completed by
- 205 young people's carers and/ or clinicians.
- 206 We repeated our nested CV process, using the same ML models using the 6 sets of most-
- 207 predictive variables, giving a total of 24 combinations of models and predictor variables,
- selecting the best performing combinations of variables and ML model, based on AUROC.
- 209 We evaluated the performance of the final models using the held-out training data. Missing
- 210 data in the test dataset was imputed using a model fit to the full training dataset, and the ND-
- GC status of each participant in the test dataset was predicted using the best ML models.
- 212 Model performance was evaluated by drawing 2000 bootstrap samples from the test dataset
- and estimating performance (AUROC and mean log loss) for the bootstrap sample. This
- 214 produced a distribution of values from which a median value and a 95% confidence interval
- 215 were calculated.

Neurodevelopmental and Psychiatric Signatures of Genomic Disorders

216 Model calibration i.e., the relationship between true and model-predicted probability of ND-217 GC status, was estimated by binning model predictions by predicted probability of ND-GC 218 status and plotting this against true ND-GC status. Model performance was also estimated 219 for male and female participants separately, and after binning participants by age quintile. 220 The importance of each variable in the best fitting model was evaluated using a permutation-221 based approach, as above. 222 The optimal threshold for converting model predicted probability of ND-GC status into a 223 binary classification was estimated by finding the threshold which maximised the j-index 224 (sensitivity + specificity -1, (39)). **Exploratory Graph Analysis** 225 226 Bootstrap Exploratory Graph Analysis (EGA) was used to investigate the dimensional 227 structure of the best performing variable set. EGA has been shown to be as accurate or 228 more accurate than traditional factor analytic methods such as parallel analysis (40,41). 229 Bootstrap EGA estimates and evaluates dimensional structure in a set of variables by first 230 applying a network estimation method (EBICglasso as applied using the ggraph package 231 (42)), followed by a community detection algorithm for weighted networks (Walktrap 232 community detection algorithm (43)). Non-parametric bootstrapping is then used to generate 233 bootstrap samples (n = 10,000) from the input dataset, and EGA was applied to each 234 replicate sample to form a sampling distribution from which the median value of each edge 235 across the replicate networks, resulting in a single network. The stability of the network can 236 be assessed by measuring the proportion of bootstrapped networks where a given variable 237 is included in each putative dimension (41), and the number of variables included can be 238 adjusted to improve the stability of dimension representations. We therefore fit an EGA 239 model to a full set of variables, then repeated the analysis with the variables with the most

consistent relationship to our dimensions (item stability > 0.75; this left 20 variables),

241 generating a stable and consistent EGA model.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Neurodevelopmental and Psychiatric Signatures of Genomic Disorders

- 242 To provide an additional assessment of the fit of the proposed dimensional structure to the
- 243 data, confirmatory factor analysis was carried out on the typical dimension structure
- identified by bootstrap EGA, with fit assessed using CFI and RMSEA.
- Finally, we repeated the above model fitting processing using the most important variables in
- each of the identified four dimensions identified by EGA.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Neurodevelopmental and Psychiatric Signatures of Genomic Disorders

247 Results

248 Study Participant Characteristics

Characteristics of study participants are given in **Supplementary Table 3** and genotypes in **Supplementary Table 1**. Individuals with an ND-GC were approximately a year younger than controls and there was a higher proportion of males in the ND-GC group. Compared to families where both a control and a ND-GC carrier took park, families where just a ND-GC carrier took part had lower parental educational level and income, and there were fewer participants of European ancestry; the discrepancy between ND-GC carriers and control individuals was due to most ND-GC carriers not having a sibling included in the study (59%).

256 Partial Least Squares Analysis

257 We applied principal components analysis (PCA) and partial least squares discriminant 258 analysis (PLSDA) to our full set of variables 233 for the 390 participants in our training dataset to describe the dimensional structure of our variables. This analysis indicated that 259 260 one component explained a particularly large proportion of the variance (16.6%, 261 **Supplementary Figure 1**), with the second and third components (5.7 and 3.9%) 262 respectively) also providing useful explanation of variation. We applied PLSDA to our 263 dataset, a supervised dimension reduction method which focusses on discrimination 264 between groups. We found that 3 components provided optimal discrimination between 265 groups, with 140, 220 and 230 variables selected for each of the three components, 266 respectively (Supplementary Figure 1). This analysis indicated that it was possible to 267 identify ND-GC carriers from controls using our dataset, with ND-GC carriers having higher 268 scores on component 1. Some individuals with a ND-GC showed similar profiles to controls 269 and likely represent participants with a ND-GC that are relatively mildly affected; some 270 controls showed profiles more like those with ND-GCs, reflecting individuals in the control sample with elevated difficulties across the measured domains. 271

. Neurodevelopmental and Psychiatric Signatures of Genomic Disorders

However, this analysis still selected large numbers of variables. We applied machine
learning approaches to develop classification models with an optimally predictive subset of
variables.

275 Developing machine learning models

276 We developed machine learning models to classify individuals by ND-GC status, including 277 artificial neural networks (ANN), linear support vector machines (SVM), penalised logistic

278 regression (LR) and random forest classifiers, using our full training set of 233 variables and

279 390 participants, with nested cross validation (CV). After nested CV, all models performed

well at distinguishing between individuals in the training data set with a ND-GC and controls,

with median AUROCs ≥ 0.9 in all cases (**Supplementary Table 4**). The SVM performed

282 best, with an overall median AUROC of 0.936. The random forest and penalised logistic

regression models did not perform significantly worse than the SVM, but the performance of

the ANN was significantly poorer (AUROC difference = -0.036, 95% credible interval of

285 difference [-0.047, -0.025]).

286 Predictive performance with optimised variable sets

We repeated model fitting using nested cross validation using the sets of variables selected as being most important to the models fit to the full set of variables (determined using permutation testing). Results were similar across multiple models and variable sets (**Figure 2A**, **Supplementary Table 5**). We selected the "SVM" variable set for further analysis as this set appeared to produce both the single best classification performance (the combination of the linear SVM model and SVM variables) and the best performance across multiple model types.

294 We then fit the best performing models to our held-out test set of data from 99 participants.

- 295 Classification performance with this test dataset was (Figure 2B, Table 1). The best
- performing model was an SVM, achieving an AUROC of 0.971 (95% CI [0.942, 0.997]) with
- a mean log loss of 0.197 (95% CI [0.110, 0.286]). This model correctly classified 72/76 ND-

298	GC carriers (94.75%) and 18/23 controls (78.3%). Performance of other models was not
299	significantly poorer than the SVM. The optimal probability for classifying a participant as a
300	ND-GC carrier, the point at which the j-index is maximised, was 0.57 (Figure 2C).
301	We investigated whether classification performance varied over participant age or between
302	genders. Performance appeared to be marginally higher in male than female participants,
303	but the difference was small, and there did not appear to be consistent differences in
304	performance across participant ages, although our sample was mostly of younger
305	participants (Supplementary Table 6).
306	Analysis of model calibration demonstrated some miss-calibration between predicted and
307	actual probabilities, with the model having some tendency to given higher-than-optimal
308	predicted probabilities of ND-GC status at higher predicted probabilities (Figure 2D).
309	We investigated variable importance in our best performing model (Figure 2E). This
310	demonstrated that a subset of variables appeared to have a particularly large importance to
311	the model. We next investigated whether there was a dimensional structure within our
312	variable set that could be used to understand the predictors of ND-GC status.

Neurodevelopmental and Psychiatric Signatures of Genomic Disorders

313 Underlying dimensional structure of selected variables

We next investigated an underlying structure of the variables included using an exploratory
graph analysis (EGA). The 30 variables used were the optimised variable set of the best
performing SVM model, determined using permutation testing. These variables included
items from the Developmental Coordination Disorder Questionnaire, Social Communication
Questionnaire, Child and Adolescent Psychiatric Assessment and the Health and
Development Questionnaire.

320 EGA fit to the most stable set of variables (20 variables were included in the final EGA

model) revealed that the variables formed a structure consisting of 4 dimensions: 1: Anxiety

322 (predominately separation anxiety and agoraphobia/fear of public places); 2: Developmental

323 Milestones and Motor Co-ordination; 3: Insomnia and 4: Depression (Figure 3,

324 Supplementary Table 7).

Confirmatory factor analysis based on this four-dimension structure demonstrated that the 4factor structure fit with RMSEA of 0.052 and CFI of 0.934, indicating a reasonable fit to the data.

328 Finally, we investigated if the variable domains identified through EGA could be used to 329 develop a further reduced set of variables for use in a ML model; although a 30-item scale 330 could be realistically used in a clinical setting, a much shorter screener could be useful in 331 busy clinical environments. We therefore selected the variable in each dimension with the 332 highest variable importance from our 30 item SVM ML model and fit a linear SVM model to 333 our training data, using these 4 variables. A linear SVM fit to 4 variables (Del [depression 334 intensity], SAP [physical symptoms of separation anxiety], InI [initial insomnia], SLT [history 335 of speech and language therapy]) had an AUROC = 0.955 [0.914, 0.993] and mean log loss 336 = 0.253 [0.203, 0.308], with 70/76 participants with an ND-GC being correctly classified 337 (92.1%), and 22/23 control participants classified correctly (95.7%). This performance was lower than the full 30 variable model, but still indicative of high absolute classification 338 339 performance.

Neurodevelopmental and Psychiatric Signatures of Genomic Disorders

340 Discussion

341 Main findings

342 In this study we demonstrate the potential of using machine learning to identify key variables 343 where individuals with genetic conditions associated with intellectual disability and 344 neurodevelopmental disorders differ from unaffected control individuals, based on a limited 345 set of psychiatric, behavioural and physical health related variables, in the absence of 346 biochemical, genetic, IQ or neurocognitive data. Using an SVM classifier, we were able to 347 classify individuals with an ND-GC with excellent performance, achieving an AUROC of 348 0.971. We identified 4 dimensions in our variable set that appeared to be most relevant to 349 identifying individuals with an ND-GC, namely, development/health, anxiety, insomnia and 350 depression.

351 Relationship to previous studies

352 Previous studies have described the high rates, and complex presentations, of psychiatric 353 and neurodevelopmental difficulties in children with ND-GCs (8,12,13,22,44). ND-GCs are 354 associated with a wide range of health outcomes (15), along with multimorbidity later in life 355 (45), and are highly enriched in the population with developmental delay/intellectual disability 356 (1,3,4,46). However, not all individuals with a ND-GC will meet diagnostic criteria for specific 357 psychiatric disorders (47). We attempted to address this by not including diagnostic status in 358 our classification models, only symptom scores; the highly accurate classification we were 359 able to achieve supports the idea that profiles of symptoms are most informative when 360 identifying areas of relative difficulty or strength in individuals with ND-GCs.

We identified 4 underlying dimensions in our final set of 30 variables. These dimensions identify potential key phenotypic areas where individuals with ND-GCs differ from controls: anxiety (particularly separation anxiety), motor skills and development, insomnia, and depression, as well as suggesting that other domains, such as difficulties with conduct or hyperactivity, may be less discriminating. The identified dimensions map onto areas of

Neurodevelopmental and Psychiatric Signatures of Genomic Disorders

difficulty elucidated in previous studies (11,27,47–50), and highlight that specific symptoms
may be particularly informative about ND-GC status, including initial insomnia, intensity of
depressive symptoms, physical symptoms of separation anxiety, and having a history of
speech and language therapy.

370 Clinical care pathways may be enhanced by focusing more on the areas identified as key 371 dimensions by our analysis if further research demonstrates that they are areas that predict 372 longer term difficulties for children with ND-GCs. It will also be important to take the items 373 identified and work with parents and clinicians to optimise the wording and content of any 374 items that could be used in a screening test derived from our analysis. For example, one 375 highly predictive item refers to a history of speech and language therapy. As ND-GC carriers 376 can struggle to access therapies in a timely fashion, this item might miss individuals who 377 might have needed speech and language therapy, but not been able to access it; therefore, 378 asking about relative difficulties with speech and language may be more informative.

379 Strength and limitations

This is the largest study of its kind to investigate the possibility of differentiation between individuals with a broad range of ND-GCs and controls based solely on psychiatric and health phenotypes using machine learning models. We were able to produce a model with very high AUROC, which appeared to perform well across a range of relevant ages, and in both males and females.

However, while including a very broad range of genomic disorders provided a more representative sample of those variants seen by clinical services, it may have increased the noise and variability in symptoms. Our sample was also unbalanced, in that there were a larger number of individuals with a ND-GC than controls, because not all families with a child with an ND-GC had an unaffected sibling of a similar age. This can affect model performance, as most techniques work best in balanced samples.

Neurodevelopmental and Psychiatric Signatures of Genomic Disorders

391 Our initial partial least squares discriminant analysis on our full dataset of phenotypic and 392 psychiatric information indicated that young people with an ND-GC and control individuals lie 393 on a spectrum of symptoms, and that while it is possible to distinguish between the two 394 groups based on psychiatric, behavioural and health information, there remain some 395 individuals with a ND-GC who have profiles that are very similar to unaffected individuals. 396 This highlights the wide variety of phenotypic expression that is seen within individuals with 397 ND-GCs, which will impose limits on the performance of any classification algorithm. 398 Additionally, ascertainment bias may affect our results. Developmental delay is a major 399 reason for referral for genetic testing in the UK, and it is likely that our sample has a 400 preponderance to include those individuals with ND-GCs who are on the more severe end of 401 the phenotypic presentation, and as such it may be the case that the common dimensional structure we identify as being associated with ND-GC carriage may be applicable only to 402 403 relatively more severe difficulties, rather than the phenotype of the entire population of ND-GC carriers. 404

Our machine learning models and EGA would be strengthened by measuring performance
and performing confirmatory factor analysis using an independent sample. Future studies
which combine measurement of most differentiating variables and longer-term follow-up of
psychiatric and health outcomes would allow the predictive accuracy of our model to be
evaluated.

We considered the role of decision curve analysis in our study, as this approach has been recommended in studies of prediction models (51). However, such calculations rely on samples being drawn from a population comparable to the clinical population. Our study sample was drawn from a cohort explicitly required to be ND-GC carriers (or sibling controls). Therefore, such an analysis is not applicable to our study. However, it should be performed in a future study validating our model in a broader population.

417 group of patients as they make up a significant proportion of those presenting to intellectual

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Neurodevelopmental and Psychiatric Signatures of Genomic Disorders

- 418 disability services and clinicians often lack complete information on prognosis for patients
- 419 with ND-GCs. This study highlights areas of difficulties for those children who may most
- 420 need further support, which may warrant further research and may be targets for
- 421 individualised interventions.
- 422 Conclusions
- 423 We demonstrate that it is possible to accurately detect individuals with ND-GCs associated
- 424 with neurodevelopmental disorders and intellectual disability based on a limited set of
- 425 psychiatric and health variables which could form the basis for clinical screening
- 426 instruments. We highlight that separation anxiety, development of motor skills and speech,
- 427 insomnia and depression are important areas where children with ND-GCs differ from
- 428 control individuals. Future research should investigate these areas in more detail so that
- 429 targeted interventions can be developed.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Neurodevelopmental and Psychiatric Signatures of Genomic Disorders

430 Acknowledgements

- 431 We are extremely grateful to all the families that participated in this study as well as to
- 432 support charities Max Appeal, The 22Crew and Unique for their help and support. We thank
- all members of the IMAGINE-ID consortium for their contributions.

It is made available under a CC-BY-NC-ND 4.0 International license . Neurodevelopmental and Psychiatric Signatures of Genomic Disorders

434 Tables

435 Table 1

Model	Mean Log Loss	AUROC	AUROC difference	AUROC
				p-value
Linear SVM	0.194 [0.112,	0.971 [0.943,	-	-
	0.279]	0.996]		
Penalised	0.250 [0.198,	0.964 [0.928,	0.007 [-0.037,	0.720
LR	0.313]	0.992]	0.05]	
Random	0.237 [0.177,	0.964 [0.931,	0.007 [-0.031,	0.774
Forest	0.306]	0.992]	0.053]	
ANN	0.411 [0.376,	0.959 [0.919,	0.012 [-0.041,	0.696
	0.446]	0.997]	0.06]	

436

437 **Table 1 Caption**: Final model performance on held-out test dataset. Values shown are

438 bootstrapped performance and the 95% confidence interval of the measure (Mean Log Loss

439 and AUROC), and difference in AUROC between the linear SVM and the other models, with

440 its 95% confidence interval, and the p-value of the AUROC difference

Neurodevelopmental and Psychiatric Signatures of Genomic Disorders

Figures 441

Neurodevelopmental and Psychiatric Signatures of Genomic Disorders

443 Figure 1



Neurodevelopmental and Psychiatric Signatures of Genomic Disorders

- Figure 1 Caption: Flowchart of analysis workflow including variable and participant 445
- 446 selection and machine learning model fitting. CV: Cross-validation; ML: Machine Learning;
- 447 PCA: Principal Components Analysis; PLSDA: Partial Least Squares Discriminant Analysis

Neurodevelopmental and Psychiatric Signatures of Genomic Disorders

449 Figure 2





Neurodevelopmental and Psychiatric Signatures of Genomic Disorders

variables by more than two ML models; Linear SVM = the top 30 most important variables
identified by a linear SVM fit to all variables. Points show the median posterior AUROC, error
bars show the 95% credible interval of the AUROC.

463 B: Receiver-operator characteristic curves for the 4 machine learning models, using the 30 464 variables from the linear SVM dataset). C: Top – histogram of predicted probability of ND-465 GC status in the 99 participants in our testing dataset using the best performing Linear SVM 466 model: Bottom - plots of sensitivity, specificity of model classification performance at 467 different thresholds for categorising a predicted probability into control or ND-GC. Optimal performance, as indexed by the j-index (sensitivity + specificity -1) occurred at a threshold 468 of 0.57. D: Calibration plot for the best performing linear SVM. The sensitivity plot compares 469 470 the predicted and true probability of participants being ND-GC carriers across 10 bins of predicted probability. Points are performance in each decile, vertical lines show 95% 471 472 confidence intervals, thick diagonal linear shows a linear model fit to the data, with the shade 473 area showing the 95% confidence interval of the linear model. A perfectly performing model 474 would following the diagonal dashed line. E: Variable importance for the best fitting model. 475 Mean dropout loss is the mean change in model AUROC after a given variable is permuted 476 (repeated 500 times). Horizontal line indicates (1 – AUROC) of the full model; therefore, 477 variables with mean values above this line have a negative impact on model fit when 478 permuted. Variable definitions: see table 6 for full definitions; SLT: Ever had speech therapy; 479 AWM: Invented words, odd indirect, metaphorical ways; CBA: catches a small ball thrown 480 from 6-8ft; CRF: runs as fast and easily as other children; SAP: Physical symptoms on 481 separation intensity; LIE: Lying; EST: educationally statemented; COB: can organise her 482 body to do a planned motor activity; SAF: Separation Anxiety if not co-sleeping with a carer; 483 ARP: say the same thing over and over; SAS: Avoidance of sleeping away from family; CCP: cuts pictures and shapes accurately; CAR: heart problems; FBI: Fear of 484 485 blood/injection; MSK: skeletal or muscular problems; FPB: Fear of activities in public 486 avoidance; REA behind in reading; SAI: Separation worries/anxiety; InI: Initial insomnia

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Neurodevelopmental and Psychiatric Signatures of Genomic Disorders

- 487 intensity; Del: Episode of depressed mood intensity; W18: walking by 18 months; LUN: other
- 488 problems with airways/lungs; AGO: Agoraphobia; InT: Insomnia intensity; BLT: Often blurts
- 489 out answers to questions; D2M: Period of 2 continuous months without depressed mood in
- 490 last year; DeQ: Distinct quality of depressed mood; RUM: Rumination; CHT: Cheating; FGT:
- 491 Forgetful in daily activities

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Neurodevelopmental and Psychiatric Signatures of Genomic Disorders

492 Figure 3



493

494

495	Figure 4 Caption: Exploratory Graph Analysis. The graph shows correlations between
496	variables (notes) as lines, where line thickness represents correlation strength. Nodes are
497	coloured by the putative dimensions they are assigned to by the Bootstrapped EGA
498	algorithm. Variable Definitions: See Table 6 for full variable definitions; AGO: Agoraphobia;
499	CBA: catches a small ball thrown from 6-8ft; CCP: cuts pictures and shapes accurately;
500	COB: can organise her body to do a planned motor activity; CRF: runs as fast and easily as
501	other children; D2M: Period of 2 continuous months without depressed mood in last year;
502	Del: Episode of depressed mood intensity; DeQ: Distinct quality of depressed mood
503	intensity; EST: educationally statemented; FPB: Fear of activities in public avoidance; InI:
504	Initial insomnia intensity; InT: Insomnia intensity; MSK: skeletal or muscular problems; REA:
505	Is your child behind in reading; SAF: Separation Anxiety; SAI: Separation worries/anxiety
506	intensity; SAP: Physical symptoms of separation intensity; SAS: Avoidance of sleeping away
507	from family intensity; SLT: Has your child had speech therapy; W18: Did your child walk by
508	18 months

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Neurodevelopmental and Psychiatric Signatures of Genomic Disorders

510 **References**

- Miller DT, Adam MP, Aradhya S, Biesecker LG, Brothman AR, Carter NP, et al.
 Consensus Statement: Chromosomal Microarray Is a First-Tier Clinical Diagnostic Test for Individuals with Developmental Disabilities or Congenital Anomalies. Am J Hum Genet. 2010 May 14;86(5):749–64.
- Smajlagić D, Lavrichenko K, Berland S, Helgeland Ø, Knudsen GP, Vaudel M, et al.
 Population prevalence and inheritance pattern of recurrent CNVs associated with
 neurodevelopmental disorders in 12,252 newborns and their parents. Eur J Hum Genet
 EJHG. 2021 Jan;29(1):205–15.
- Yang EH, Shin YB, Choi SH, Yoo HW, Kim HY, Kwak MJ, et al. Chromosomal
 Microarray in Children With Developmental Delay: The Experience of a Tertiary Center
 in Korea. Front Pediatr. 2021;9:690493.
- Yuan H, Shangguan S, Li Z, Luo J, Su J, Yao R, et al. CNV profiles of Chinese pediatric patients with developmental disorders. Genet Med Off J Am Coll Med Genet. 2021
 Apr;23(4):669–78.
- Rees E, Walters JTR, Georgieva L, Isles AR, Chambert KD, Richards AL, et al. Analysis
 of copy number variations at 15 schizophrenia-associated loci. Br J Psychiatry.
 2014;204(2):108–14.
- Devlin B, Scherer SW. Genetic architecture in autism spectrum disorder. Curr Opin Genet Dev. 2012;22(3):229–37.
- 530 7. Coe BP, Witherspoon K, Rosenfeld J a, van Bon BWM, Vulto-van Silfhout AT, Bosco P,
 531 et al. Refining analyses of copy number variation identifies specific genes associated
 532 with developmental delay. Nat Genet. 2014 Sep 14;46(10):1063–71.
- Niarchou M, Zammit S, van Goozen SH, Thapar A, Tierling HM, Owen MJ, et al.
 Psychopathology and cognition in children with 22q11.2 deletion syndrome. Br J
 Psychiatry. 2013/10/12 ed. 2014;204(1):46–54.
- 536 9. Eaton CB, Thomas RH, Hamandi K, Payne GC, Kerr MP, Linden DEJ, et al. Epilepsy
 537 and seizures in young people with 22q11.2 deletion syndrome: Prevalence and links with
 538 other neurodevelopmental disorders. Epilepsia [Internet]. 2019 [cited 2019 Apr 15];0(0).
 539 Available from: https://onlinelibrary.wiley.com/doi/abs/10.1111/epi.14722
- 540 10. Cunningham A, Delport S, Cumines W, Busse M, Linden D, Hall J, et al. Developmental
 541 coordination disorder, psychopathology and IQ in 22q11.2 deletion syndrome. Br J
 542 Psychiatry. 2017 Jan 4;212(01):27–33.
- 543 11. Moulding HA, Bartsch U, Hall J, Jones MW, Linden DE, Owen MJ, et al. Sleep problems
 544 and associations with psychopathology and cognition in young people with 22q11.2
 545 deletion syndrome (22q11.2DS). Psychol Med. 2019 May 5;50(7):1191–202.
- 546 12. Schneider M, Debbané M, Bassett AS, Chow EWC, Fung WLA, Van Den Bree MBM, et
 547 al. Psychiatric disorders from childhood to adulthood in 22q11.2 deletion syndrome:
 548 Results from the international consortium on brain and behavior in 22q11.2 deletion
 549 syndrome. Am J Psychiatry. 2014/03/01 ed. 2014;171(6):627–39.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Neurodevelopmental and Psychiatric Signatures of Genomic Disorders

- 13. Chawner SJRA, Owen MJ, Holmans P, Raymond FL, Skuse D, Hall J, et al. Genotype–
 phenotype associations in children with copy number variants associated with high
 neuropsychiatric risk in the UK (IMAGINE-ID): a case-control cohort study. Lancet
 Psychiatry. 2019 May 2;
- 14. Kendall KM, Rees E, Escott-Price V, Einon M, Thomas R, Hewitt J, et al. Cognitive
 Performance Among Carriers of Pathogenic Copy Number Variants: Analysis of 152,000
 UK Biobank Subjects. Biol Psychiatry. 2017 Jul 15;82(2):103–10.
- 557 15. Crawford K, Bracher-Smith M, Owen D, Kendall KM, Rees E, Pardiñas AF, et al. Medical
 558 consequences of pathogenic CNVs in adults: analysis of the UK Biobank. J Med Genet.
 559 2018 Oct 20;jmedgenet-2018-105477.
- 16. Niarchou M, Martin J, Thapar A, Owen MJ, van den Bree MBM. The clinical presentation
 of attention deficit-hyperactivity disorder (ADHD) in children with 22q11.2 deletion
 syndrome. Am J Med Genet Part B Neuropsychiatr Genet Off Publ Int Soc Psychiatr
 Genet. 2015 Dec;168(8):730–8.
- Jopp DA, Keys CB. Diagnostic overshadowing reviewed and reconsidered. Am J Ment
 Retard AJMR. 2001 Sep;106(5):416–33.
- 18. Reiss S, Szyszko J. Diagnostic overshadowing and professional experience with
 mentally retarded persons. Am J Ment Defic. 1983 Jan;87(4):396–402.
- Mason J, Scior K. 'Diagnostic Overshadowing' Amongst Clinicians Working with People
 with Intellectual Disabilities in the UK. J Appl Res Intellect Disabil. 2004;17(2):85–90.
- 570 20. Gothelf D, Gruber R, Presburger G, Dotan I, Brand-Gothelf A, Burg M, et al.
 571 Methylphenidate treatment for attention-deficit/hyperactivity disorder in children and
 572 adolescents with velocardiofacial syndrome: an open-label study. J Clin Psychiatry. 2003
 573 Oct;64(10):1163–9.
- 574 21. Tyrer F, Dunkley AJ, Singh J, Kristunas C, Khunti K, Bhaumik S, et al. Multimorbidity
 575 and lifestyle factors among adults with intellectual disabilities: a cross-sectional analysis
 576 of a UK cohort. J Intellect Disabil Res JIDR. 2019 Mar;63(3):255–65.
- 577 22. Wolstencroft J, Wicks F, Srinivasan R, Wynn S, Ford T, Baker K, et al. Neuropsychiatric
 578 risk in children with intellectual disability of genetic origin: IMAGINE, a UK national
 579 cohort study. Lancet Psychiatry. 2022 Aug 3;S2215-0366(22)00207-3.
- 23. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and
 Guidelines for the Interpretation of Sequence Variants: A Joint Consensus
 Recommendation of the American College of Medical Genetics and Genomics and the
 Association for Molecular Pathology. Genet Med Off J Am Coll Med Genet. 2015
 May;17(5):405–24.
- Angold A, Prendergast M, Cox A, Harrington R, Simonoff E, Rutter M. The Child and
 Adolescent Psychiatric Assessment (CAPA). Psychol Med. 2009 Jul 9;25(04):739.
- 587 25. Goodman R. The extended version of the Strengths and Difficulties Questionnaire as a
 588 guide to child psychiatric caseness and consequent burden. J Child Psychol Psychiatry.
 589 1999 Jul;40(5):791–9.
- Solution 26. Rutter M, Bailey A, Lord C. Social Communication Questionnaire. Los Angeles, CA:
 Western Psychological Services; 2003.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Neurodevelopmental and Psychiatric Signatures of Genomic Disorders

- 592 27. Cunningham AC, Hall J, Owen MJ, van den Bree MBM. Coordination difficulties, IQ and
 593 psychopathology in children with high-risk copy number variants. Psychol Med. 2019;1–
 594 10.
- 28. Van Aken K, Swillen A, Beirinckx M, Janssens L, Caeyenberghs K, Smits-Engelsman B.
 Kinematic movement strategies in primary school children with 22q11 . 2 Deletion
 Syndrome compared to age- and IQ-matched controls during visuo-manual tracking.
 Res Dev Disabil. 2010;31(3):768–76.
- 599 29. Wilson BN, Crawford SG. The Developmental Coordination Disorder Questionnaire
 2007. Phys Occup Ther Pediatr. 2012;29(2):182–202.
- 30. Development Core Team R. R: A Language and Environment for Statistical Computing.
 R Found Stat Comput Vienna Austria. 2011;0:{ISBN} 3-900051-07-0.
- 31. Collins GS, Reitsma JB, Altman DG, Moons KGM. Transparent reporting of a
 multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the
 TRIPOD statement. BMJ. 2015 Jan 7;350:g7594.
- 32. Rohart F, Gautier B, Singh A, Lê Cao KA. mixOmics: An R package for 'omics feature
 selection and multiple data integration. PLoS Comput Biol. 2017 Nov;13(11):e1005752.
- 33. Friedman J, Hastie T, Tibshirani R. Regularization Paths for Generalized Linear Models
 via Coordinate Descent. J Stat Softw. 2010;33(1):1–22.
- 34. Wright MN, Ziegler A. ranger: A Fast Implementation of Random Forests for High
 Dimensional Data in C++ and R. J Stat Softw. 2017 Mar 31;77:1–17.
- 612 35. Karatzoglou A, Smola A, Hornik K, Zeileis A. kernlab An S4 Package for Kernel
 613 Methods in R. J Stat Softw. 2004 Nov 2;11:1–20.
- 614 36. Venables WN, Ripley BD. Modern Applied Statistics with S [Internet]. Springer Verlag;
 615 2002 [cited 2022 Jul 28]. Available from: https://link.springer.com/book/10.1007/978-0616 387-21706-2
- Kuhn M, Johnson K. Applied Predictive Modeling [Internet]. Springer Verlag; 2013 [cited
 2022 Jul 28]. Available from: https://link.springer.com/book/10.1007/978-1-4614-6849-3
- 38. Biecek P. DALEX: Explainers for Complex Predictive Models in R. J Mach Learn Res.
 2018;19(84):1–5.
- 39. Youden WJ. Index for rating diagnostic tests. Cancer. 1950 Jan;3(1):32–5.
- 40. Christensen AP, Golino H. Estimating Factors with Psychometric Networks: A Monte
 Carlo Simulation Comparing Community Detection Algorithms [Internet]. PsyArXiv; 2020
 [cited 2021 Mar 17]. Available from: https://psyarxiv.com/hz89e/
- 41. Christensen AP, Golino H. Estimating the stability of the number of factors via Bootstrap
 Exploratory Graph Analysis: A tutorial [Internet]. PsyArXiv; 2019 [cited 2021 Mar 17].
 Available from: https://psyarxiv.com/9deay/
- 42. Epskamp S, Cramer AOJ, Waldorp LJ, Schmittmann VD, Borsboom D. qgraph: Network
 Visualizations of Relationships in Psychometric Data. J Stat Softw. 2012 May
 24;48(1):1–18.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Neurodevelopmental and Psychiatric Signatures of Genomic Disorders

- 631 43. Csardi G, Nepusz T. The igraph software package for complex network research. 632 InterJournal. 2006;Complex Systems:1695.
- 633 44. Steinman KJ, Spence SJ, Ramocki MB, Proud MB, Kessler SK, Marco EJ, et al. 16p11.2 deletion and duplication: Characterizing neurologic phenotypes in a large clinically 634 635 ascertained cohort. Am J Med Genet A. 2016 Nov;170(11):2943-55.
- 636 45. Chawner SJ, Watson CJ, Owen MJ. Clinical evaluation of patients with a 637 neuropsychiatric risk copy number variant. Curr Opin Genet Dev. 2021 Jun 1;68:26-34.
- 638 46. Cooper GM, Coe BP, Girirajan S, Rosenfeld JA, Vu T, Baker C, et al. A Copy Number 639 Variation Morbidity Map of Developmental Delay. Nat Genet. 2011 Aug 14:43(9):838–46.
- 640 47. Chawner SJRA, Doherty JL, Anney RJL, Antshel KM, Bearden CE, Bernier R, et al. A 641 Genetics-First Approach to Dissecting the Heterogeneity of Autism: Phenotypic 642 Comparison of Autism Risk Copy Number Variants. Am J Psychiatry. 2021 Jan 643 1;178(1):77-86.
- 644 48. Chawner S, Evans A, Williams N, Owen SM, Hall J, Bree M van den, Sleep disturbance 645 as a transdiagnostic marker of psychiatric risk in children with neurodevelopmental risk 646 genetic condition [Internet]. 2022 [cited 2022 Nov 10]. Available from: 647 https://europepmc.org/article/PPR/PPR529736
- 648 49. Cunningham AC, Hall J, Einfeld S, Owen MJ, Bree MBM van den. Emotional and 649 behavioural phenotypes in young people with neurodevelopmental CNVs. medRxiv. 650 2020 Jan 29;2020.01.28.20019133.
- 50. Kendall KM, Rees E, Bracher-Smith M, Legge S, Riglin L, Zammit S, et al. Association of 651 Rare Copy Number Variants With Risk of Depression. JAMA Psychiatry. 2019 Aug 652 653 1;76(8):818-25.
- 654 51. Meehan AJ, Lewis SJ, Fazel S, Fusar-Poli P, Steverberg EW, Stahl D, et al. Clinical 655 prediction models in psychiatry: a systematic review of two decades of progress and 656 challenges. Mol Psychiatry. 2022 Jun;27(6):2700-8.
- 657 52. Carpenter B, Gelman A, Hoffman MD, Lee D, Goodrich B, Betancourt M, et al. Stan: A 658 Probabilistic Programming Language. J Stat Softw. 2017 Jan 11;76(1):1–32.
- 659 53. Makowski D, Ben-Shachar MS, Chen SHA, Lüdecke D. Indices of Effect Existence and 660 Significance in the Bayesian Framework. Front Psychol [Internet]. 2019 [cited 2021 Apr 661 15];10. Available from: https://www.frontiersin.org/articles/10.3389/fpsyg.2019.02767/full

Neurodevelopmental and Psychiatric Signatures of Genomic Disorders

Supplementary Items 663

Supplementary Methods 664

Initial Variable Filtering 665

666 The initial dataset contained 1450 variables with information from 589 individuals (441 667 individuals with a ND-GC and 148 unaffected control individuals). To prepare the data for 668 analysis, we began by removing those variables that contained administrative, free text and 669 date and time information, as well as variables that were not quantitative questionnaire 670 responses or coding of symptom intensity. Following these initial steps, variables where the 671 most common response made up greater than 95% of responses to the question were removed as these items would likely not be useful in distinguishing young people with ND-672 673 GCs and phenotypic difficulties from other young people. In addition, those variables with a 674 missing rate greater than 25% were also removed. Once the variables had been filtered, 675 individuals with missing data rates across the remaining variables greater than 25% were also removed. These steps resulted in 489 individuals (376 ND-GC carriers [76.9%], of 676 whom 41% had at least one sibling also included in the study) and 233 variables retained for 677 678 further analysis.

679 Principal Components Analysis and Partial Least Squares Discriminant Analysis

680 To develop an initial understanding of the dimensional structure of our data, we applied principal components analysis (PCA) followed by partial least squares discriminant analysis 681 682 (PLSDA) to our training dataset, using the R mixOmics package (32). We used PCA as an 683 initial unsupervised approach to identify the number of components that explained variance 684 in our measured variables. Next, we applied a supervised approach (where the outcome 685 was ND-GC status): sparse PLSDA. The number of components retained and number of 686 variables per component were selected using 5-fold cross-validation, repeated 50 times, 687 finding the combination that minimised prediction distance using one-sided t-tests testing for

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Neurodevelopmental and Psychiatric Signatures of Genomic Disorders

- 688 significant differences in the mean error rate when components are added to the model. The
- 689 PLSDA model was then fit with the optimal number of components and variables.
- 690 Model Evaluation
- 691 Elastic net regression models optimised penalty and mixture parameters; random forests
- used 1000 trees and optimised minimal node size and number of variables split at each
- node; SVM models optimised cost and margin parameters, neural network models optimised
- the number of hidden units, epochs and model penalty.
- 695 Model performance was evaluated for each outer fold by fitting the model with the best
- 696 performing set of hyperparameters in the inner fold data to the (previously unseen) outer fold
- assessment dataset. This process was then repeated for all outer folds.
- 698 Following nested cross validation, we compared model performance based on the AUROC
- 699 values for each outer fold, using a Bayesian linear mixed model fit with the R rstanarm
- package (52), where the outer fold identity was included as a varying intercept. From this
- 701 model we calculated the performance of each model using the median of the posterior
- distribution, and the 95% credible interval using the highest density interval method. Models
- were then compared using the probability of direction method (53).
- 704 Modell variable importance was determined using permutation testing. This approach
- randomly permutes data from each variable in turn and evaluates the change in model
- performance (i.e., change in AUROC) following permutation. This was repeated 500 times to
- 707 give a distribution of changes in performance after permutation. Variables with greater
- importance to the model will cause larger drops in AUROC than variables with lower
- 709 importance

Neurodevelopmental and Psychiatric Signatures of Genomic Disorders

Supplementary Table 1 710

711

Genetic Condition	Ν
Controls	104
16p11.2 proximal deletion	45
15q11.2 deletion	39
22q11.2 proximal deletion	30
1q21.1 distal duplication	28
15q13.3 deletion	24
16p11.2 proximal duplication	24
22q11.2 proximal duplication	23
15q13.3 duplication	20
1q21.1 distal deletion	17
NRXN1 deletion	15
1q21.1 proximal TAR duplication	13
16p11.2 distal deletion	11
Kleefstra Syndrome	11
15q11.2 duplication	5
Other ND-GC*	80

712

Supplementary Table 1 Caption: Counts of the genotypes of all study participants. *To 713

714 preserve the confidentiality of individuals who had ND-GCs with a total count of < 5

715 participants with the same ND-GC in the study, we have grouped all such low frequency ND-

- 716 GCs into a single group. This group contained 31 deletions and 25 duplications, with 15
- 717 other conditions being related to mixed deletions and duplications, single nucleotide
- 718 variants, triplications, translocation, chromosomal trisomy, or imprinting. Chromosomal

It is made available under a CC-BY-NC-ND 4.0 International license . Neurodevelopmental and Psychiatric Signatures of Genomic Disorders

- 719 regions affected by ND-GCs in this group were: 1p21, 1p33, 1p36, 1q21, 1q42, 1q44, 2p12,
- 720 2p16, 2q11-q21, 2q13, 2q33, 2q34, 2q37, 3q28-29, 4p15, 4q28-31, 5p15, 5q23, 6p25, 6q27,
- 721 7p22, 7q11, 8q21, 8q24, 9p24, 9q34, 11q23, 12p13, 15pter-q13, 15q11, 15q11-q13, 15q13,
- 722 16p11, 16p12, 16p13, 16p21, 16q23, 17p11, 17p13, 17q12, 17q23, 17q25, 18p11, 20q13,
- 723 22q11, 22q12-q13, 22q13, Xp21, Xp22, Xp28.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Neurodevelopmental and Psychiatric Signatures of Genomic Disorders

725 Supplementary Table 2: TRIPOD Table

Section/Topic	١	Checklist Item	Page
Title and abstract	:		
Title	1	Identify the study as developing and/or validating a multivariable prediction model, the target population, and the outcome to be predicted.	Title
Abstract	2	Provide a summary of objectives, study design, setting, participants, sample size, predictors, outcome, statistical analysis, results, and conclusions.	Abstract
Introduction			
Background and objectives	3а	Explain the medical context (including whether diagnostic or prognostic) and rationale for developing or validating the multivariable prediction model, including references to existing models.	Introduction
	3b	Specify the objectives, including whether the study describes the development or validation of the model or both.	Introduction
Methods			
Source of data	4a	Describe the study design or source of data (e.g., randomized trial, cohort, or registry data), separately for the development and validation data sets, if applicable.	Methods and Materials - Participants
	4b	Specify the key study dates, including start of accrual; end of accrual; and, if applicable, end of follow-up.	Methods and Materials - Assessments
	5a	Specify key elements of the study setting (e.g., primary care, secondary care, general population) including number and location of centres.	Methods and Materials - Participants
Participants	5b	Describe eligibility criteria for participants.	Methods and Materials - Participants
	5c	Give details of treatments received, if relevant.	N/A – observational study

Neurodevelopmental and Psychiatric Signatures of Genomic Disorders

	6a		Methods and
		Clearly define the outcome that is predicted by the prediction model,	Materials -
Outcome			Participants
			N/A
	6b	Report any actions to blind assessment of the outcome to be predicted.	observational
			study
		Clearly define all predictors used in developing or validating the	Methods and
	7a	multivariable prediction model, including how and when they were	Materials -
Predictors		measured.	Assessments
		Poport any actions to blind assessment of predictors for the outcome and	N/A
	7b		observational
		other predictors.	study
			Methods and
Sample size	8	Explain how the study size was arrived at.	Materials -
			Participants
	9		Methods and
		Describe how missing data were handled (e.g., complete-case analysis, single imputation, multiple imputation) with details of any imputation	Materials – Initial
			Variable Filtering
Missing data			and Machine
		method.	Learning Model
			Fitting
			Methods and
			Materials – Initial
	10-		Variable Filtering
	10a	Describe how predictors were handled in the analyses.	and Machine
Statistical			Learning Model
analysis			Fitting
methods			Methods and
			Materials -
	10b	Specify type of model, all model-building procedures (including any	Machine
		predictor selection), and method for internal validation.	Learning Model
			Fitting
1	1		1

Neurodevelopmental and Psychiatric Signatures of Genomic Disorders

			Methods and
			Materials –
	104	Specify all measures used to assess model performance and, if relevant,	Machine
	iou	to compare multiple models.	Learning Model
			Fitting –
			paragraph 1
Risk groups	11	Provide details on how risk groups were created, if done.	N/A
Results			
		Describe the flow of participants through the study, including the number	
	13a	of participants with and without the outcome and, if applicable, a summary	Figure 1
Participants		of the follow-up time. A diagram may be helpful.	
i anticipants		Describe the characteristics of the participants (basic demographics,	
	13b	clinical features, available predictors), including the number of participants	Table 1
		with missing data for predictors and outcome.	
Model	14a	Specify the number of participants and outcome events in each analysis.	Table 1
development	146	If done, report the unadjusted association between each candidate	N/Δ
dovolopmont		predictor and outcome.	14/7 (
			Results –
			Predictive
			performance
		Present the full prediction model to allow predictions for individuals (i.e.,	with optimised
	15a	all regression coefficients, and model intercept or baseline survival at a	variable sets;
		given time point).	Shiny app
			https://nadonnell
Model			<u>y.shinyapps.io/c</u>
specification			<u>nv_ml_app/</u>
			Results-
			Predictive
			performance
	15b	Explain how to the use the prediction model.	with optimised
			variable sets;
			Shiny App
			https://nadonnell

Neurodevelopmental and Psychiatric Signatures of Genomic Disorders

<u>y.shinyapps.io/c</u>
<u>nv_ml_app/</u>
Results –
Developing
machine learning
models, Results
- Predictive
performance
with optimised
variable sets
Discussion –
Strengths and
limitations
Discussion –
Main Findings,
Discussion –
Relationship to
previous studies
Discussion -
Conclusions
Methods and
Materials –
Statistical
Analysis
Funding
statement

726

Supplementary Table 2 Caption: TRIPOD Reporting Guideline Table 727

Neurodevelopmental and Psychiatric Signatures of Genomic Disorders

Supplementary Table 3 729

Variable		Group		
	Overall,	Sibling	ND-GC,	p-
	N = 489 ¹	Control,	N = 376 ¹	value ²
		N = 113 ¹		
Age	9.33	10.35	9.02	<0.001
	(7.27, 12.22)	(8.13, 13.11)	(7.12, 11.79)	
Gender				0.001
Female	180 (37%)	56 (50%)	124 (33%)	
Male	309 (63%)	57 (50%)	252 (67%)	
Highest Educational				0.001
Level				
No School Leaving Exams	32 (6.5%)	4 (3.5%)	28 (7.4%)	
Low	102 (21%)	22 (19%)	80 (21%)	
Middle	174 (36%)	38 (34%)	136 (36%)	
High	128 (26%)	25 (22%)	103 (27%)	
Unknown	53 (11%)	24 (21%)	29 (7.7%)	
Income				0.009
<=£19,999	123 (25%)	21 (19%)	102 (27%)	
£20,000 - £39,999	164 (34%)	35 (31%)	129 (34%)	
£40,000 - £59,999	73 (15%)	14 (12%)	59 (16%)	
£60,000 +	71 (15%)	20 (18%)	51 (14%)	
Unknown	58 (12%)	23 (20%)	35 (9.3%)	
Ethnicity				<0.001
European	435 (89%)	92 (81%)	343 (91%)	
Other	31 (6.3%)	5 (4.4%)	26 (6.9%)	

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Neurodevelopmental and Psychiatric Signatures of Genomic Disorders

Unknown	23 (4.7%)	16 (14%)	7 (1.9%)	
¹ Median (IQR); n (%)				
² Wilcoxon rank sum test; Pe				

730

731 **Supplementary Table 3 Caption**: Demographic information about the sample of children

732 affected by a ND-GC and sibling controls.

Neurodevelopmental and Psychiatric Signatures of Genomic Disorders

Supplementary Table 4 733

Model	Performance	Difference	Probability of Direction
Linear SVM	0.936 [0.917, 0.955]	-	1
Random Forest	0.933 [0.915, 0.952]	-0.002 [-0.014, 0.008]	0.654
Penalised LR	0.928 [0.909, 0.947]	-0.008 [-0.019, 0.003]	0.172
ANN	0.9 [0.881, 0.919]	-0.036 [-0.047, -0.025]	0

734

735 Supplementary Table 4 Caption: Classification performance for each of the different

736 machine learning techniques using training data and all variables. ANN: Artificial Neural

Network; LR: Logistic Regression; SVM: Support Vector Machine 737

Neurodevelopmental and Psychiatric Signatures of Genomic Disorders

Supplementary Table 5 739

Model	Variable Set	Performance	Difference	Probability
				of Direction
Linear SVM	SVM	0.944 [0.923,	-	1
		0.964]		
Penalised LR	SVM	0.938 [0.918,	-0.005 [-0.021,	0.506
		0.959]	0.011]	
ANN	SVM	0.935 [0.915,	-0.008 [-0.025,	0.310
		0.956]	0.008]	
Random	SVM	0.942 [0.921,	-0.002 [-0.018,	0.814
Forest		0.962]	0.014]	
Linear SVM	Penalised I R	0 942 [0 922	-0.002[-0.018	0.812
		0.0001	0.01.41	0.012
		0.963]	0.014]	
Penalised LR	Penalised LR	0.935 [0.914,	-0.009 [-0.025,	0.300
		0.955]	0.007]	
ANN	Penalised LR	0.905 [0.885,	-0.038 [-0.054, -	0
		0.926]	0.022]	
Random	Penalised LR	0.936 [0.917,	-0.007 [-0.024,	0.384
Forest		0.958]	0.009]	
Linear SVM	ANN	0.925 [0.904,	-0.019 [-0.035, -	0.022
		0.945]	0.002]	
Penalised LR	ANN	0.926 [0.905,	-0.018 [-0.034, -	0.030
		0.946]	0.002]	
ANN	ANN	0.922 [0.901,	-0.022 [-0.038, -	0.008
		0.942]	0.006]	

Neurodevelopmental and Psychiatric Signatures of Genomic Disorders

Random	ANN	0.937 [0.916,	-0.007 [-0.023,	0.418
Forest		0.957]	0.009]	
Linear SVM	Random	0.938 [0.918,	-0.006 [-0.022,	0.492
	Forest	0.959]	0.011]	
Penalised LR	Random	0.933 [0.912,	-0.011 [-0.027,	0.184
	Forest	0.953]	0.005]	
ANN	Random	0.917 [0.896,	-0.027 [-0.043, -	0
	Forest	0.938]	0.011]	
Random	Random	0.942 [0.921,	-0.002 [-0.018,	0.842
Forest	Forest	0.962]	0.015]	
Linear SVM	All Variables	0.933 [0.914,	-0.01 [-0.027,	0.214
		0.955]	0.006]	
Penalised LR	All Variables	0.926 [0.905,	-0.018 [-0.034, -	0.028
		0.946]	0.002]	
ANN	All Variables	0.898 [0.877,	-0.046 [-0.062, -	0
		0.919]	0.03]	
Random	All Variables	0.931 [0.91,	-0.013 [-0.029,	0.120
Forest		0.951]	0.003]	
Lincor C\/M	Variables	0.044[0.022		0.086
Linear SVM	variables	0.944 [0.923,	0[-0.016, 0.016]	0.986
	selected by >	0.964]		
	1 model			
Penalised LR	Variables	0.936 [0.915,	-0.008 [-0.023,	0.350
	selected by >	0.956]	0.009]	
	1 model			

Neurodevelopmental and Psychiatric Signatures of Genomic Disorders

ANN	Variables	0.923 [0.902,	-0.021 [-0.037, -	0.012
	selected by >	0.943]	0.005]	
	1 model			
Random	Variables	0.938 [0.918,	-0.006 [-0.022,	0.498
Forest	selected by >	0.959]	0.01]	
	1 model			
Linear SVM	Variables	0 944 [0 923	0[-0.017_0.016]	0.082
	Vanabies	0.044 [0.020,	0[-0.017, 0.010]	0.302
	selected by >	0.964]		
	2 models			
Penalised LR	Variables	0.94 [0.92,	-0.003 [-0.019,	0.704
	selected by >	0.962]	0.013]	
	2 models			
	2 11100010			
ANN	Variables	0.934 [0.914,	-0.01 [-0.026,	0.234
	selected by >	0.955]	0.006]	
	2 models			
Random	Variables	0.939 [0.918,	-0.005 [-0.021,	0.568
Forest	selected by >	0.959]	0.011]	
	2 models			

740

741 Supplementary Table 5 Caption: Classification performance for each of the different

742 machine learning techniques using training data and different sets of variables. Column

743 Performance is the median model performance over 20 outer folds of nested cross

744 validation, estimated using a Bayesian generalised linear model, with 95% credible interval;

745 Column Difference shows the model estimated difference in performance between the top

746 performing model (Linear SVM with the top 30 model important variables estimated by the

747 linear SVM fit to all variables) and a given model

Neurodevelopmental and Psychiatric Signatures of Genomic Disorders

Supplementary Table 6 748

749

Covariate	Value	AUROC	Mean Log Loss
Age (quintile)	[5.89,6.72]	1	0.105
	(6.72,8.57]	0.964	0.288
	(8.57,9.41]	1	0.28
	(9.41,12.2]	1	0.108
	(12.2,21.6]	0.987	0.201
Gender	Female	0.949	0.312
	Male	0.99	0.132

750

751 Supplementary Table 6: Performance statistics split by age and gender

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Neurodevelopmental and Psychiatric Signatures of Genomic Disorders

753 Supplementary Table 7

Variable Name	Variable Definition	Dimension
SAP	Separation Anxiety: do they get aches and pains, feel sick, get headaches etc. on school days, or at other times when separated from a parent/carer (Binary Variable)	1: Anxiety
SAI	Separation Anxiety: Excessive worries or fear concerning separation from the persons to whom the child is attached (Binary Variable)	1: Anxiety
FPB	Fear of activities in public: does fear of activities in public lead to a restricted lifestyle (Binary Variable)	1: Anxiety
SAS	Separation Anxiety: Avoidance, or attempted avoidance, of sleeping away from family, as a result of worrying or anxiety about separation from home or family (Binary Variable)	1: Anxiety
SAF	Separation Anxiety: The child sleeps with a family member because of persistent refusal to sleep through the night without being near a major attachment figure (Binary Variable)	1: Anxiety
AGO	Agoraphobia: Does agoraphobia lead to a restricted lifestyle (Binary Variable)	1: Anxiety
EST	Health and Development: Is your child educationally statemented? (Binary Variable)	2: Development/ Co-ordination
SLT	Health and Development: Has your child had speech therapy? (Binary Variable)	2: Development/ Co-ordination
W18	Health and Development: Did your child walk by 18 months of age? (Binary Variable)	2: Development/ Co-ordination

Neurodevelopmental and Psychiatric Signatures of Genomic Disorders

СВА	Coordination and motor development: Your child catches a small ball (e.g. tennis ball size) thrown	2: Development/ Co-ordination
	from a distance of 6-8 feet (1.8-2.4 metres) (Ordinal	
	variable: 1: Not at all like your child; 2: A bit like your	
	child; 3: Moderately like your child; 4: Quite a bit like	
	your child; 5: Extremely like your child)	
CRF	Coordination and motor development: Your child	2: Development/
	runs as fast and in a similar way to other children of	Co-ordination
	the same age and gender (Ordinal variable: 1: Not	
	at all like your child; 2: A bit like your child; 3:	
	Moderately like your child; 4: Quite a bit like your	
	child; 5: Extremely like your child)	
СОВ	Coordination and motor development: If your child	2: Development/
	has a plan to do a motor activity, they can organise	Co-ordination
	their body to follow the plan and effectively	
	complete the task (e.g., building a cardboard or	
	cushion 'fort', moving on playground equipment,	
	building a house or a structure with blocks, or using	
	craft materials) (Ordinal variable: 1: Not at all like	
	your child; 2: A bit like your child; 3: Moderately like	
	your child; 4: Quite a bit like your child; 5: Extremely	
	like your child)	
ССР	Coordination and motor development: Your child	2: Development/
	cuts pictures and shapes accurately (Ordinal	Co-ordination
	variable: 1: Not at all like your child; 2: A bit like your	
	child; 3: Moderately like your child; 4: Quite a bit like	
	your child; 5: Extremely like your child)	

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Neurodevelopmental and Psychiatric Signatures of Genomic Disorders

REA	Health and Development: Is your child behind in	2: Development/
	reading? (Binary Variable)	Co-ordination
MSK	Health and Development: Has your child had	2: Development/
	skeletal or muscular problems? (Binary Variable)	Co-ordination
InT	Insomnia: Does the child experience overall	3: Insomnia
	insomnia greater than 1 hour per night? (Binary	
	Variable)	
Inl	Insomnia: Is initial insomnia present (Does it take	3: Insomnia
	more than an hour to get to sleep at night?) (Binary	
	Variable)	
Del	Depression: Was there a week when the participant	4: Depression
	felt miserable most days? (Binary Variable)	
D2M	Depression: Has there been a period of two months	4: Depression
	in the last year when the participant did not feel	
	depressed in mood? (Binary Variable)	
DeQ	Depression: Depressed mood has a subjectively	4: Depression
	different quality from sadness, contrasted with an	
	experience that caused sadness, such as loss of a	
	pet or watching a sad film (Binary variable)	

754

755 **Supplementary Table 7 Caption**: Final variables and associated dimensions identified

756 using bootstrap exploratory graph analysis.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Neurodevelopmental and Psychiatric Signatures of Genomic Disorders

757 Supplementary Figure 1



Supplementary Figure 1 Caption: PCA and PLSDA. A: Variance explained by the first 10
principal components of all 233 variables in 390 participants in the training dataset. One
component explains a particularly large proportion of variance (16.6%). B: scatter plot of all
participants by the first two PLSA components, with 95% confidence ellipse for each class.
C: as B, for PLS components 1 and 3.